INTRODUCTION
============

Although the advances in the early detection and the treatment modalities of breast cancer have achieved the improved survival, there is still a significant number of mortalities. Breast cancer is the leading contributor of to cancer mortality in women, and there are more than one million new cases per year throughout the world \[[@B1]\]. Cancer metastasis is a crucial factor in the prediction of the disease progression and patient survival, and the axillary lymph node (ALN) is known to be the most frequent metastatic site. the metastasis of ALN is an essential component in determining the tumor stage and the treatment strategies \[[@B2]\].

Cancer development is a result of the complex genetic and epigenetic alterations, and these genetic changes eventually affect the cancer cell progression and metastasis \[[@B3]\]. In the last several decades, a group of genes called the tumor suppressor genes have been researched. These genes are expressed in the normal tissues but not in the cancer tissues, where the tumor suppressor genes are frequently silenced and hypermethylated at the promoter regions in the cancer tissues \[[@B4]\]. In particular, the hypermethylation of the CpG island, where the CpGs are concentrated, leads to an inactivation of these tumor suppressor genes, ultimately leading to the inability to impede malignant transformation \[[@B5]\]. To date, several studies have revealed the hypermethylated and silenced genes at the promoter regions in the breast cancer cells \[[@B4]\]. For example, the mismatch repair genes *hMLH1* and *hMSH2* are mutated in breast cancer \[[@B6]\]; and the retinoic acid beta 2 (RARβ2) receptor is methylated and silenced in a fraction of breast cancers, which leads to the breast cancer progression \[[@B7]\].

The *CDH1* gene encodes for the transmembrane glycoprotein E-cadherin that is involved in the epithelial cell adhesion, and a loss of its expression is associated with the release of invasive tumor cells from the primary tumor \[[@B8]\]. In general, the *CDH1* mutation results in a loss of the E-cadherin expression and is detected in a diffuse type gastric cancer and the infiltrative lobular carcinoma of the breast \[[@B9],[@B10]\]. Recent studies have reported that a reduced or absent E-cadherin expression is also found in the invasive ductal carcinoma of the breast \[[@B11]\]. Furthermore, hypermethylation of the *CDH1* gene was reported to involve the sentinel lymph node metastasis \[[@B12]\]. However, there are not enough studies on the role of the hypermethylation of the *CDH1* gene in the axillary lymph node metastasis and the prognosis for the Korean breast cancer patients.

For this reason, we evaluated the methylation status of the *CDH1* genes in the primary and the matched metastatic ALN to evaluate the role of the *CDH1* gene in the ALN metastasis. We also analyzed and compared the clinicopathologic characteristics and prognosis of the patients according to the methylation status of *CDH1*.

METHODS
=======

Patients and tissue samples
---------------------------

A total of 92 patients, who had undergone breast cancer surgery because from the primary breast cancer and a concurrent ALN metastasis between April 2002 and December 2004 in the Korea University Hospital, Seoul, Korea were selected. The selection criteria for this study included 1) diagnosis with invasive ductal carcinoma; 2) ALN metastasis at the same time of surgery or within 1 month after surgery; 3) enough tumor tissues both in the primary lesion and in the metastatic ALN; and 4) without preoperative chemotherapy or radiation therapy. The carcinomas with massive necrosis or the inflammatory carcinoma were also excluded, as these cancer tissues pose difficulties in the cancer cell extraction to assure the suitable sample quality. At last, 61 patients were selected. The study was approved by the Korea University Anam Hospital Institutional Review Board.

All cancer tissues were routinely processed and diagnosed. The histology was confirmed by a pathologist. The estrogen and progesterone receptor status were evaluated in the primary tumor by the standard immunohistochemistry (Dako, Glostrup, Denmark). The tumors were considered positive if more than 1% of the cells showed nuclear staining. HER2 status was determined on the primary tumor tissues with the anti-HER2 monoclonal antibody (Lab Vision, Kalamazoo, USA); and considered positive if the staining intensity score was 3 or a score 2 with a fluorescence in situ hybridization positive. The stage of cancer was classified according to the 7th edition of tumor, node, metastasis system (TNM) by the American Joint Committee on Cancer (AJCC) \[[@B2]\].

DNA extraction
--------------

The cancer area was marked on the hematoxylin-eosin (H&E) stained slides of the primary tumors and the metastatic ALNs. The corresponding area from 4 to 5 tissue sections of 4-µm thick, formalin-fixed and paraffin-embedded tissue blocks were scraped. The tissue sections were deparaffinized in xylene followed by ethanol incubation. Genomic DNA was isolated using a GENE ALL™ Tissue SV Kit (GeneAll Biotechnology, Seoul, Korea) according to the manufacturer\'s recommendation. Briefly, the tissue samples were digested with proteinase K, and the DNA samples were bound to columns, washed and eluted. All paraffin-fixed tissues were centrifuged with 1,200-µL xylene and washed with ethanol. After being mixed with 20-µL proteinase K solution, the deparaffinized tissues were incubated at 56℃ for 2 hours. Finally, SV column and buffer were added in the tubes and centrifuged with the tissue samples. Supernatants were used for sodium-bisulfite modification.

Sodium-bisulfite modification
-----------------------------

Extracted DNA was modified with sodium bisulfite using the EZ DNA Methylation™ Kit (Zymo Research, Orange, USA) following the kit protocols. Purified DNA was denatured with a dilution buffer and incubated with the CT conversion reagent (Zymo research) at 50℃ for 12 to 16 hours. The modified DNA was applied to columns (Zymo-Spin™ IC Column; Zymo Research) and centrifuged with 100-µL wash buffer. After the washing phase, 200-µL desulphonation buffer was added to the column, and the DNA was incubated at room temperature (20-30℃) for 20 minutes. Finally, the substrates were centrifuged at 30 seconds with an elution buffer. In this modification, the unmethylated cytosines were converted to uracils, whereas the methylated cytosines were unaffected in the reaction and remained as cytosines.

Methylation specific polymerase chain reaction
----------------------------------------------

The sodium bisulfite-converted DNA was amplified with Blend Taq®Plus (Toyobo, Osaka, Japan), using specific primers in the optimizing annealing temperature ([Table 1](#T1){ref-type="table"}) \[[@B13]\]. The DNA samples were predenatured at 94℃ for 2 minutes. Subsequently, the polymerase chain reaction (PCR) amplification was accomplished using a 35 timed cycles of denaturation at 94℃ for 30 seconds, annealing for 30 seconds and extension at 72℃ for 1 minute, according to the manufacturer\'s indication. The postmethylation specific PCR products were loaded on the SeaKem® LE Agarose (Lonza, Rockland, USA) and analyzed using electrophoresis. [Figure 1](#F1){ref-type="fig"} represents the status of methylation on the agarose gel after the electrophoresis. We used 100 bp DNA Ladder Marker (Enzynomics, Daejeon, Korea) as a molecular weight marker and the breast cancer cell line MDA-MB-231 as a positive marker, which demonstrated the methylation and silencing of the *CDH1* \[[@B14],[@B15]\].

Statistical analysis
--------------------

Descriptive analyses were performed to explore the clinicopathologic characteristics and the methylation status. Pearson\'s chi-square test or Fisher\'s exact test was used for binomial comparison. Logistic regression test was used for the multivariate analysis. We used the Cox hazard regression method to estimate the relapse-free survival and the disease-specific survival according to the methylation status.

Data were analyzed using Microsoft Excel 2007® (Microsoft Corp., Redmond, USA). The statistical analyses were performed using PASW® Statistics version 18.0 (SPSS Inc., Chicago, USA). Reported *p*-values were two-sided, and the statistical significance was set at *p*\<0.05.

RESULTS
=======

Clinicopathologic characteristics of the patients
-------------------------------------------------

Characteristics of the 61 patients included in this study are presented in [Table 2](#T2){ref-type="table"}. All patients were female, and the mean age at diagnosis was 47.1 years (range, 30-72 years). According to the AJCC TNM stage \[[@B2]\], T2 (33 patients, 54.1%), N1 (40 patients, 65.6%), and stage IIB (23 patients, 36.1%) were most common in each of the subgroups. Fifty-nine cases were invasive ductal carcinomas, not otherwise specified, and two cases were mixed with tubular carcinoma and mucinous carcinoma. Thirty-two cases (52.5%) were classified as the poorly differentiated histologic grade (G3). The hormone receptor and HER-2 status were assessed in all primary tumors. Thirty-seven cases (60.7%) were estrogen receptor positive, and 33 cases (54.1%) were progesterone receptor positive. HER2 was overexpressed in 25 cases (41.0%) of primary tumors.

Frequency of methylation status of *CDH1* gene in primary and metastatic tumors
-------------------------------------------------------------------------------

The methylated rate of the *CDH1* gene in the primary tissues and the metastatic ALNs is described in [Table 3](#T3){ref-type="table"}. The methylation rate of *CDH1* gene was higher in the metastatic node than in the primary site (60.7% vs. 45.9%, *p*\<0.05). In addition, we compared the association of the methylation status between the primary and the matched axillary node ([Table 4](#T4){ref-type="table"}). Ten cases of the unmethylated primary tumors were methylated in the matched metastatic lymph nodes, while only one case of the methylated primary tumor was unmethylated in the matched lymph node.

Correlation of methylation status and clinicopathologic features
----------------------------------------------------------------

The methylated status and the clinicopathologic characteristics were analyzed with the univariate and multivariate methods ([Table 5](#T5){ref-type="table"}). The analyses contained these factors: patient age, tumor stage, histologic grade, hormone receptor status, HER2/*neu* overexpression and lymphovascular invasion status. In univariate and multivariate analysis, the methylation status of the *CDH1* gene in the primary tumor was not associated with any variables ([Table 5](#T5){ref-type="table"}). However, *CDH1* methylation in the metastatic ALN was correlated with a poor histologic grade in logistic regression analysis ([Table 6](#T6){ref-type="table"}).

Methylation status and clinical outcomes
----------------------------------------

After a median follow-up of 88 months (range, 1-138 months), 18 cases of any local or distant recurrences and 8 cases of disease-specific mortality were occurred. The overall 5-year cumulative relapse-free rate was 76.0%±5.8% and disease-specific survival rate was 85.4%±4.8%. The univariate analysis showed that the methylation status either in the primary lesion or the metastatic ALNs was not correlated with relapse-free survival (RFS) and disease-specific survival (DSS). For patients who had methylated primary tumor, the 5-year cumulative relapse-free rate was 66.7%±9.7%, and the disease-specific survival rate was 83.8%±7.4%, compared with 79.5%±7.6% (*p*=0.131) and 86.6%±6.2% (*p*=0.697) in patients who had the nonmethylated primary tumor. Patients who had methylated ALNs also did not show statistical differences for RFS (*p*=0.895) and DSS (*p*=0.184) in the univariate analysis.

To exclude the potential confounders, the databases were adjusted for the age, T, N stage, tumor grade, presence of lymphovascular invasion, estrogen receptor expression, use of chemotherapy, and use of hormone therapy using multivariate analysis. [Figure 2](#F2){ref-type="fig"} describes the adjusted cumulative RFS rate according to the methylated status of the primary tumor and the metastatic lymph node. Hypermethylation of the *CDH1* primer in the primary tumor was significantly correlated with poor RFS (*p*=0.046), while the status of hypermethylation in the metastatic axillary node was not correlated with RFS (*p*=0.105). The methylation status of the *CDH1* gene in the primary and metastatic axillary node had no significant correlations with of DSS (*p*=0.911 and *p*=0.906, respectively).

DISCUSSION
==========

Although breast cancer is a highly metastatic disease, prognosis may be milder if it is diagnosed prior to the metastasis. ALN is the most common and the first metastatic site, and the status of the ALN plays an important role in the prediction of breast cancer prognosis \[[@B16]\]. To date, there has been a lack of satisfying tools in preoperatively identifying the ALN metastasis in the early breast cancer patients. ALN dissection and sentinel lymph node (SLN) biopsy are invaluable methods in recognizing the presence of the tumor cells \[[@B17],[@B18]\]. In this study, the metastatic status of ALN was recognized with a SLN biopsy (18 cases) and initial ALN dissection (43 cases). Because SLN biopsy and ALN dissection may cause some complications including pain, numbness, lymphedema and a limitation of the arm movement \[[@B19]\], an alternative less invasive method to detect the ALN metastasis is necessary.

The methylation of several tumor suppressor genes is a well-known mechanism of the oncogenesis in breast cancer \[[@B3],[@B6],[@B7]\]. Identifying the methylation pattern of the specific genes related with the axillary lymph node metastasis may be a crucial key to understanding the disease progression and metastasis \[[@B12],[@B20]\]. In this study, we focused on the relationship between the methylation of the specific tumor suppressor gene and the ALN metastasis. The hypothesis of this study was that if the specific tumor suppressor genes were related with the tumor metastasis, the hypermethylation of these genes would be identified in the metastatic axillary lymph node in an equal or higher frequency as in the primary lesion \[[@B20]\].

*CDH1* is known as a E-cadherin gene and located on chromosome 16q22.1. Recent studies have reported that a loss of E-cadherin expression is associated with the nodal metastasis \[[@B21]\] and distant metastasis including those in the bone, brain, and lungs \[[@B22]\]. Hypothesizing on the hypermethylation frequency of the tumor suppressor genes in the metastatic axillary lymph node, our results have shown that the methylation of *CDH1* is detected more frequently in the metastatic ALN than in primary tumor. Comparing the primary tumor and its matched ALN, *CDH1* was more frequently methylated in the matched metastatic lesion. Based on these results, we suggest that *CDH1* may be involved in the ALN metastasis.

Some studies have reported that the reduced E-cadherin expression may be associated with the poor prognostic factors, such as a high histologic grade, nodal metastasis and a loss of hormone receptor expression \[[@B23],[@B24]\]. On the other hand, Singhai et al. \[[@B25]\] reported that a loss of E-cadherin expression did not show a correlation with the prognostic variables. So far, there has been a debate on the relationship between the E-cadherin expression and prognosis. In this study, we found that the *CDH1* methylation in the metastatic ALN was correlated with a high histologic grade in the multivariate analysis. Furthermore, we also demonstrated that the hypermethylation of *CDH1* in the primary lesion was significantly correlated with the RFS.

In general, the HER2 positive breast cancer patients compose approximately 15% to 20% of all breast cancers cases \[[@B26]\]. The HER2 positive rate is reported to increase up to 40% in the aggressive tumor characters and the high-stage disease \[[@B27]\]. In this study, the patient demographic showed a high rate of HER2 receptor expression (41.0%). More than half of the cases were of the poorly differentiated histologic grade (G3), and all the carcinomas had axillary metastasis. The high rate of HER2 expression in this study may arise from the aggressive study cohort. The expression of the HER2 receptor is a well known prognostic factor in breast cancer \[[@B28]\]. Hence, there may be a question of the high rate of HER2 expression affecting the worse prognosis of patients with the *CDH1* methylated tumor. We performed the multivariate analysis to exclude the potential confounders including HER2 expression, and our analysis showed that the HER2 expression did not affect the disease progression (*p*=0.437 in the RFS, and *p*=0.411 in the DSS) in this study cohort.

One of the limitations in this study was that we did not show the relation between the E-cadherin expression level and the *CDH1* methylation status. While we planned to analyze the E-cadherin expression level according to the *CDH1* methylation status, the correlation of the *CDH1* methylation and the E-cadherin expression have been well-established in several studies \[[@B29],[@B30]\]. As such, we focused on the effects of the *CDH1* hypermethylation to the axillary metastasis and prognosis.

In conclusion, this study demonstrated that the methylation status of the tumor suppressor genes was different in the primary breast cancer and the matched metastatic axillary lymph node; and that the methylation rate of *CDH1* was higher in the metastatic node than the primary site. We suggest that the hypermethylation of *CDH1* may be extended from the primary tumor to the axillary metastatic node during the tumor progression. In addition, the methylation status of *CDH1* was associated with a poor RFS in both the primary tumor and the metastatic axillary lymph node. Taken together, we suggest that the methylation status of the *CDH1* gene may be a promising biomarker for assessing the disease status in the breast cancer.
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![Representative methylation-specific polymerase chain reaction results for the *CDH1* genes. Note the unmethylated primary tumor and the metastatic axillary lymph node in patient 1 (hollow arrows). Solid arrows (patient 2) indicate the methylated primary tumor and the metastatic axillary lymph node.\
P=primary tumor; LN=axillary lymph node; M.W.=molecular weight (bp=base pair); P.C.=positive control; M=methylated tissue; U=unmethylated tissue.](jbc-16-16-g001){#F1}

![Multivariate analysis curves for the relapse-free survival (RFS) according to the methylation status. (A) RFS according to the methylation status of the primary tumor (*p*=0.046). (B) RFS according to the methylation status of the metastatic axillary node (*p*=0.352).\
Primary=methylation status in primary tumor; LN=methylation status in axillary lymph node.](jbc-16-16-g002){#F2}
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Primers for methylation specific polymerase chain reaction of *CDH1* gene

![](jbc-16-16-i001)

M=methylated; U=unmethylated; Tm=adequate temperature for annealing; bp=base pair.
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Clinicopathologic characteristics of 61 patients
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AJCC=American Joint Committee on Cancer; IDC=invaisive ductal carcinoma; NOS=not otherwise specified; LVI=lymphovascular invasion; ER=estrogen receptor; PR=progesterone receptor.

^\*^IDC mixed with tubular carcinoma, IDC mixed with mucinous carcinoma.
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Methylation status of *CDH1* genes in primary cancer tissues and metastatic axillary nodes
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Data are presented as number (%).
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The association of methylation status between primary tumor and metastatic axillary node
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LN=lymph node; M=methylated; U=unmethylated.
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Univariate and multivariate analysis of tumor methylation in primary tumor
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Data are presented as number (%).

AJCC=American Joint Committee on Cancer; ER=estrogen receptor; PR=progesterone receptor; LVI=lymphovascular invasion.

^\*^Mean±SD; ^†^*p*-value of univariate analysis; ^‡^*p*-value of multivariate analysis.
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Univariate and multivariate analysis of tumor methylation in metastatic axillary node
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Data are presented as number (%).

AJCC=American Joint Committee on Cancer; ER=estrogen receptor; PR=progesterone receptor; LVI=lymphovascular invasion.

^\*^Mean±SD; ^†^*p*-value of univariate analysis; ^‡^*p*-value of multivariate analysis.
